BridgeBio is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines for genetic diseases and cancers with clear genetic drivers. Founded in 2015, the company has a portfolio of 20+ drug development programs and offices in the US, Canada, and Switzerland, focusing on scientific excellence and rapid execution.